New approaches to cancer therapy

Annals of Oncology

Volumn 14, Issue 6, 2003, Pages 813-816

  Garattini, S ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE INHIBITOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CANCER VACCINE; CAPECITABINE; CISPLATIN; COMBRETASTATIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450; DOCETAXEL; FLUOROURACIL; GEFITINIB; GROWTH FACTOR RECEPTOR; IMATINIB; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROCARBAZINE; PROTEASOME; PROTEIN FARNESYLTRANSFERASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RETINOID; RITUXIMAB; TAMOXIFEN; TEMOZOLOMIDE; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR;

APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOPROPHYLAXIS; CHRONIC LEUKEMIA; CYTOTOXICITY; DIETARY INTAKE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; FOLLICULAR LYMPHOMA; FOOD DRUG INTERACTION; GASTROINTESTINAL STROMAL TUMOR; GENE THERAPY; GLIOBLASTOMA; HUMAN; LIFESTYLE; LUNG NON SMALL CELL CANCER; NUTRITION; PRIORITY JOURNAL; QUALITY OF LIFE; TESTIS CANCER;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; ENZYME INHIBITORS; GENE THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 0037674327     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg261     Document Type: Editorial

References (56)

1. Levi F, Lucchini F, Negri E, La Vecchia C. The decline in cancer mortality in the European Union, 1988-1996. Eur J Cancer 2000; 36: 1965-1968.
2. Garattini S, La Vecchia C. Perspectives in cancer chemotherapy. Eur J Cancer 2001; 37: S128-S147.
3. Bailar JC 3rd, Gornick HL. Cancer undefeated. N Engl J Med 1997; 336: 1569-1574.
4. Garattini S, Bertele V. Efficacy, safety, and cost of new anticancer drugs. Br Med J 2002; 325: 269-271.
5. White CA, Weaver RL, Grillo-Lopez AJ. Antibody-targeted immunotherapy for treatment of malignancy. Annu Rev Med 2001; 52: 125-145.
6. Grillo-Lopez AJ. Monoclonal antibody therapy for B-cell lymphoma. Int J Hematol 2002; 76: 385-393.
7. Di Gaetano N, Xiao Y, Erba E et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001; 114: 800-809.
8. CPMP. European Public Assessment Report: Herceptin. [Online] http://www.eudra.org/humandocs/Humans/EPAR/Herceptin/Herceptin.htm (26 March 2003, date last accessed).
9. Batchelor T. Temozolomide for malignant brain tumours. Lancet 2000; 355: 1115-1116.
10. Mader RM, Schrolnberger C, Rizovski B et al. Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer. Br J Cancer 2003; 88: 782-787.
11. Buchdunger E, Zimmermann J, Mett H et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100-104.
12. Zimmermann J, Buchdunger E, Mett H et al. Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives. Bioorg Med Chem Lett 1997; 7: 187-192.
13. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001; 98: 2039-2042.
14. Demetry GD, von Mehren, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
15. Gambacorti-Passerini CB, Gunby RH, Piazza R et al. Molecular mechanisms of resistance to imatinib in Philadelphia chromosome-positive leukaemias. Lancet Oncol 2003; 4: 75-85.
16. Albanell J, Rojo F, Averbuch S et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD 1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20: 110-124.
17. Willett WC, Trichopoulos D. Nutrition and cancer: a summary of the evidence. Cancer Causes Control 1996; 7: 178-180.
18. Osborne M, Boyle P, Lipkin M. Cancer prevention. Lancet 1997; 349 (Suppl): 27-30.
19. Anonymous. Prevention of cancer in the next millennium: Report of the Chemoprevention Working Group to the American Association for Cancer Research. Cancer Res 1999; 59: 4743-4758.
20. Gamet-Payrastre L, Li P, Lumeau S et al. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res 2000; 60: 1426-1433.
21. Phang JM, Poore CM, Lopaczynska J, Yeh GC. Flavonol-stimulated efflux of 7,12-dimethylbenz(a) anthracene in multidrug-resistant breast cancer cells. Cancer Res 1993; 53: 5977-5981.
22. Phillips RK, Wallace MH, Lynch PM et al. A randomised, double-blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002; 50: 857-860.
23. De Palo G, Veronesi U, Camerini T et al. Can fenretinide protect women against ovarian cancer? J Natl Cancer Inst 1995; 87: 146-147.
24. Chiesa F, Tradati N, Marazza M et al. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem 1993; 2 (Suppl 17F): 55-61.
25. Decensi A, Bruno S, Costantini M et al. Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end point. J Natl Cancer Inst 1994; 86: 138-140.
26. Hong WK, Endicott J, Itri LM et al. 13-Cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986; 315: 1501-1505.
27. Hong WK, Lippman SM, Itri LM et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323: 795-801.
28. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.
29. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000; 60: 203-212.
30. Huang X, Molema G, King S et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997; 275: 547-550.
31. Chaplin DJ, Pettit GR, Parkins CS, Hill SA. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer 1996; 27: S86-S88.
32. Gottesman MM, Hrycyna CA, Schoenlein PV et al. Genetic analysis of the multidrug transporter. Annu Rev Genet 1995; 29: 607-649.
33. Volm M. Multidrug resistance and its reversal. Anticancer Res 1998; 18: 2905-2917.
34. Den Boer ML, Pieters R, Veerman AJ. Mechanisms of cellular anthracycline resistance in childhood acute leukemia. Leukemia 1998; 12: 1657-1670.
35. Pegg AE, Dolan ME, Moschel RC. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 1995; 51: 167-223.
36. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921.
37. Mologni L, Ponzanelli I, Bresciani F et al. The novel synthetic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) causes apoptosis in acute promyelocytic leukemia cells through rapid activation of caspases. Blood 1999; 93: 1045-1061.
38. Gudas LJ, Sporn MB, Roberts AB. Cellular biology and biochemistry of retinoids. In Sporn MB, Roberts AB, Goodman DS (eds): The Retinoids: Biology, Biochemistry and Medicine. New York, NY: Raven Press 1994; 443-520.
39. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-572.
40. Meng L, Kwok BH, Sin N, Crews CM. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res 1999; 59: 2798-2801.
41. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-2392.
42. Mallams AK, Njoroge FG, Doll RJ et al. Antitumor 8-chlorobenzocy-cloheptapyridines: a newclass of selective, nonpeptidic, nonsulfhydryl inhibitors of ras farnesylation. Bioorg Med Chem 1997; 5: 93-99.
43. Cholody WM, Hernandez L, Hassner L et al. Bisimidazoacridones and related compounds: new antineoplastic agents with high selectivity against colon tumors. J Med Chem 1995; 38: 3043-3052.
44. Tabernero L, Verdaguer N, Coll M et al. Molecular structure of the A-tract DNA dodecamer d(CGCAAATTTGCG) complexed with the minor groove binding drug netropsin. Biochemistry 1993; 32: 8403-8410.
45. Valoti G, Nicoletti MI, Pellegrino A et al. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res 1998; 4: 1977-1983.
46. van'tveer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-535.
47. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci USA 2003; 100: 776-781.
48. Phang JM, Poore CM, Lopaczynska J, Yeh GC. Flavonol-stimulated efflux of 7,12-dimethylbenz(a) anthracene in multidrug-resistant breast cancer cells. Cancer Res 1993; 53: 5977-5981.
49. Critchfield JW, Welsh CJ, Phang JM, Yeh GC. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem Pharmacol 1994; 48: 1437-1445.
50. Christensen JG, LeBlanc GA. Reversal of multidrug resistance in vivo by dietary administration of the phytochemical indole-3-carbinol. Cancer Res 1996; 56: 574-581.
51. Anonymous. Prevention of cancer in the next millennium: report of the Chemoprevention Working Group to the American Association for Cancer Research. Cancer Res 1999; 59: 4743-4758.
52. Maniotis AJ, Folberg R, Hess A et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 155: 739-752.
53. Donelli MG, Broggini M, Colombo T, Garattini S. Importance of the presence of necrosis in studying drug distribution within the tumor tissue. Eur J Drug Metab Pharmacokinet 1977; 2: 63-67.
54. Donelli MG, Colombo T, Broggini M, Garattini S. Differential distribution of antitumoral agents in primary and secondary tumors. Cancer Treat Rep 1977; 61: 1319-1324.
55. D'Incalci M, Farina P, Sessa C et al. Hexamethylmelamine distribution in patients with ovarian and other pelvic cancers. Cancer Treat Rep 1982; 66: 231-235.
56. Parmiani G, Pilla L, Castelli C, Rivoltini L. Vaccination of patients with solid tumours. Ann Oncol 2002; 14: 817-824.